Lbp Am Sa Sells 4,733 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

LBP AM SA lessened its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 15.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 25,133 shares of the company's stock after selling 4,733 shares during the quarter. LBP AM SA's holdings in Neurocrine Biosciences were worth $3,431,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Sigma Planning Corp purchased a new position in shares of Neurocrine Biosciences during the 3rd quarter valued at approximately $230,000. GSA Capital Partners LLP boosted its stake in shares of Neurocrine Biosciences by 441.3% during the 3rd quarter. GSA Capital Partners LLP now owns 8,682 shares of the company's stock valued at $1,000,000 after buying an additional 7,078 shares during the last quarter. Victory Capital Management Inc. boosted its stake in shares of Neurocrine Biosciences by 48.5% during the 3rd quarter. Victory Capital Management Inc. now owns 204,205 shares of the company's stock valued at $23,529,000 after buying an additional 66,662 shares during the last quarter. Oppenheimer & Co. Inc. boosted its stake in shares of Neurocrine Biosciences by 11.9% during the 3rd quarter. Oppenheimer & Co. Inc. now owns 19,289 shares of the company's stock valued at $2,222,000 after buying an additional 2,051 shares during the last quarter. Finally, KBC Group NV boosted its stake in shares of Neurocrine Biosciences by 78.3% during the 3rd quarter. KBC Group NV now owns 18,972 shares of the company's stock valued at $2,186,000 after buying an additional 8,332 shares during the last quarter. Hedge funds and other institutional investors own 92.59% of the company's stock.

Remove Ads

Insider Buying and Selling at Neurocrine Biosciences

In other news, Director Kevin Charles Gorman sold 2,707 shares of Neurocrine Biosciences stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $152.92, for a total transaction of $413,954.44. Following the completion of the sale, the director now directly owns 517,030 shares in the company, valued at $79,064,227.60. The trade was a 0.52 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Kyle Gano sold 65,000 shares of Neurocrine Biosciences stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $141.50, for a total value of $9,197,500.00. Following the sale, the chief executive officer now owns 135,392 shares of the company's stock, valued at approximately $19,157,968. This represents a 32.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 233,178 shares of company stock valued at $33,906,594 in the last 90 days. 4.30% of the stock is currently owned by corporate insiders.

Neurocrine Biosciences Stock Performance

Shares of NASDAQ:NBIX traded down $0.24 during midday trading on Thursday, reaching $110.07. The company had a trading volume of 870,132 shares, compared to its average volume of 957,818. Neurocrine Biosciences, Inc. has a 1-year low of $105.18 and a 1-year high of $157.98. The firm has a market cap of $10.97 billion, a price-to-earnings ratio of 33.46, a price-to-earnings-growth ratio of 0.77 and a beta of 0.35. The company has a fifty day simple moving average of $128.06 and a two-hundred day simple moving average of $125.36.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last released its quarterly earnings results on Thursday, February 6th. The company reported $1.00 earnings per share for the quarter, missing analysts' consensus estimates of $1.62 by ($0.62). Neurocrine Biosciences had a net margin of 14.49% and a return on equity of 13.38%. Analysts expect that Neurocrine Biosciences, Inc. will post 4.28 EPS for the current year.

Neurocrine Biosciences announced that its Board of Directors has initiated a stock buyback plan on Friday, February 21st that permits the company to buyback $500.00 million in shares. This buyback authorization permits the company to repurchase up to 4.2% of its stock through open market purchases. Stock buyback plans are often an indication that the company's board of directors believes its shares are undervalued.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. Morgan Stanley reiterated an "overweight" rating and set a $150.00 target price (down from $185.00) on shares of Neurocrine Biosciences in a research note on Friday, March 7th. HC Wainwright reissued a "buy" rating and set a $185.00 price target on shares of Neurocrine Biosciences in a research report on Friday, February 21st. UBS Group upped their price target on Neurocrine Biosciences from $162.00 to $176.00 and gave the company a "buy" rating in a research report on Thursday, January 30th. Piper Sandler reissued an "overweight" rating and set a $160.00 price target on shares of Neurocrine Biosciences in a research report on Monday, December 23rd. Finally, Wedbush dropped their price target on Neurocrine Biosciences from $157.00 to $147.00 and set an "outperform" rating on the stock in a research report on Friday, February 7th. Five investment analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Neurocrine Biosciences has a consensus rating of "Moderate Buy" and an average price target of $165.24.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.